Table 6.

Ongoing phase II clinical trials of Hb-HDACIs in solid tumors [127].

Disease	Compound	Regimen	No. Pts.	End-Point	ClinicalTrials. gov Identifier
Relapsed/refractorysarcomas-age 4–21 years	Vorinostat	Vorinostat: orally on a daily × 4 schedule +Etoposide: at a fixed dose i.v. daily × 3 days	50	DLT MTD RR	NCT01294670
HER2-positive locally recurrent or metastatic breast cancer	Vorinostat	Vorinostat: 300 mg × 4 days on, then 3 days off +Lapatinib: 1,250 mg daily	47	CB	NCT01118975
Metastatic RCC	Vorinostat	Vorinostat: escalating doses PO BID on days 1–14 +Bevacizumab: IV on day 1 of a 21-day cycle	42	MTD PFS	NCT00324870
Advanced soft tissue sarcomas	Vorinostat	Vorinostat: orally once daily for 14 days + Bortezomib: IV on days 1, 4, 8, 11 of a 21-day cycle	45	RR	NCT00937495
Metastatic NSCLC	Belinostat	Belinostat: dose escalation with starting dose 1 g/m2 i.v. on days 1-5 of a 21-day cycle +Carboplatin AUC 6 +Paclitaxel 200 mg/m2	35	MTD	NCT01310244
Recurrent GBM	Panobinostat	Panobinostat: orally three times per week every other week +Bevacizumab: i.v. on days 1 and 15 of a 28-day cycle	67	MTD PFS	NCT00859222
Advanced sarcomas	Abexinostat	Abexinostat: orally on days 1–5 +Doxorubicin on day 4 of a 21-day cycle	47	MTD RR	NCT01027910
K-Ras mutated advanced CRC	Resminostat	Resminostat: orally +OLFIRI i.v.	80	MTD PFS	NCT01277406
HCC pretreated with sorafenib	Resminostat	orally	60	PFS	NCT00943449

Abbreviations: CB, clinical benefit rate; CRC, colorectal carcinoma; DLT, dose limiting toxicity; GBM, glioblastoma multiforme; HCC, hepatocellular carcinoma; MBC, metastatic breast cancer; MDT, maximum tolerated dose; NSCLC, non small cell lung cancer; PFS, progression free survival; RCC, renal cell carcinoma; RR, objective response rate.